Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.99 HKD | +0.67% | -1.97% | -19.84% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company appears to be poorly valued given its net asset value.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.84% | 1.44B | B- | ||
+32.09% | 693B | C+ | ||
+29.39% | 584B | B | ||
-1.34% | 372B | C+ | ||
+20.34% | 332B | B- | ||
+7.39% | 294B | C+ | ||
+14.25% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+8.49% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 2186 Stock
- Ratings Luye Pharma Group Ltd.